Timolol is a non-selective β blocker which is used for increased intra-ocular pressure. In 2010, Guo and Ni first reported the clinical response to timolol 0.5% solution in a 4-month-old infant who had a thin haemangioma plaque on the upper eyelid.[48] Subsequently, several pilot studies and case series have shown its clinical efficacy.[49505152] It has been mostly used for localized, non-ulcerated superficial IHs. Chan et al. found timolol to be more effective for lesions with a mean diameter of <11.3 mm (i.e. 100 mm3 in volume) as compared to larger lesions.[53] It is to be applied two times a day. One drop of timolol maleate (0.5%) contains 0.25 mg of the drug.[53] It is recommended to apply 1 drop of the gel two times a day. Some authors recommend 3-4 times application.[52] Timolol does not penetrate deeply and hence it is not useful in deep haemangiomas.[52] Treatment is more effective in the proliferative phase than in the involution phase, and also, plaques respond better than nodules.[53]